Literature DB >> 25715048

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae.

Miguel O'Ryan1, Roberto Vidal, Felipe del Canto, Juan Carlos Salazar, David Montero.   

Abstract

Efforts to develop vaccines for prevention of acute diarrhea have been going on for more than 40 y with partial success. The myriad of pathogens, more than 20, that have been identified as a cause of acute diarrhea throughout the years pose a significant challenge for selecting and further developing the most relevant vaccine candidates. Based on pathogen distribution as identified in epidemiological studies performed mostly in low-resource countries, rotavirus, Cryptosporidium, Shigella, diarrheogenic E. coli and V. cholerae are predominant, and thus the main targets for vaccine development and implementation. Vaccination against norovirus is most relevant in middle/high-income countries and possibly in resource-deprived countries, pending a more precise characterization of disease impact. Only a few licensed vaccines are currently available, of which rotavirus vaccines have been the most outstanding in demonstrating a significant impact in a short time period. This is a comprehensive review, divided into 2 articles, of nearly 50 vaccine candidates against the most relevant viral and bacterial pathogens that cause acute gastroenteritis. In order to facilitate reading, sections for each pathogen are organized as follows: i) a discussion of the main epidemiological and pathogenic features; and ii) a discussion of vaccines based on their stage of development, moving from current licensed vaccines to vaccines in advanced stage of development (in phase IIb or III trials) to vaccines in early stages of clinical development (in phase I/II) or preclinical development in animal models. In this first article we discuss rotavirus, norovirus and Vibrio cholerae. In the following article we will discuss Shigella, Salmonella (non-typhoidal), diarrheogenic E. coli (enterotoxigenic and enterohemorragic), and Campylobacter jejuni.

Entities:  

Keywords:  ALA, aminolevulenic acid; ASC, antibody secreting cell; Ace, accessory cholera enterotoxin; CT, cholera toxin; CT-A cholera toxin A subunit; CT-B cholera toxin B subunit; Cep, core encoded pilus; E. coli; ETEC; ETEC, enterotoxigenic E. coli; GEMS, global enteric multi-center study; HA/P, hemaglutinin protease; HBGA, histo-blood group antibodies; IS, intussusception; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; LB, lower boundary; LLR, Lanzhou Lamb Rotavirus vaccine; LPS, lipopolysaccharide; MPL, monophosphoril lipid A; MSH, mannose-sensitive hemaglutinin pilus; REST, rotavirus efficacy and safety trial; RITARD; RR, relative risk, CI, confidence interval; RecA, recombinase A; SAES, serious adverse events; SRSV, small round virus, ORF, open reading frame; STEC; STEC, shigatoxin producing E. coli; TCP, toxin co-regulated pilus; V. cholerae; VA1.3, vaccine attempt 1.3; VLP, virus like particle; VLPs, virus like particles, VRPs, virus replicon particles; VP, viral proteins; WHO, World Health Organization; Zot, zonula occludens toxin; acute diarrhea; campylobacter; enteric pathogens; gastroenteritis; norovirus; removable intestinal tie-adult rabbit diarrhea; rotavirus; salmonella; shigella; vaccines

Mesh:

Substances:

Year:  2015        PMID: 25715048      PMCID: PMC4514277          DOI: 10.1080/21645515.2015.1011019

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  151 in total

1.  Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks.

Authors:  Wilbur H Chen; Richard N Greenberg; Marcela F Pasetti; Sofie Livio; Michael Lock; Marc Gurwith; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2013-10-30

Review 2.  Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea.

Authors:  Tanvir Ahmed; Taufiqur R Bhuiyan; K Zaman; David Sinclair; Firdausi Qadri
Journal:  Cochrane Database Syst Rev       Date:  2013-07-05

3.  Proposal for a unified norovirus nomenclature and genotyping.

Authors:  Annelies Kroneman; Everardo Vega; Harry Vennema; Jan Vinjé; Peter A White; Grant Hansman; Kim Green; Vito Martella; Kazuhiko Katayama; Marion Koopmans
Journal:  Arch Virol       Date:  2013-04-25       Impact factor: 2.574

Review 4.  Epidemiology of human noroviruses and updates on vaccine development.

Authors:  Sasirekha Ramani; Robert L Atmar; Mary K Estes
Journal:  Curr Opin Gastroenterol       Date:  2014-01       Impact factor: 3.287

5.  Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Authors:  Suvi Lappalainen; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

6.  Intussusception risk after rotavirus vaccination in U.S. infants.

Authors:  W Katherine Yih; Tracy A Lieu; Martin Kulldorff; David Martin; Cheryl N McMahill-Walraven; Richard Platt; Nandini Selvam; Mano Selvan; Grace M Lee; Michael Nguyen
Journal:  N Engl J Med       Date:  2014-01-14       Impact factor: 91.245

Review 7.  The state-of-the-art of approved and under-development cholera vaccines.

Authors:  M Pastor; J L Pedraz; A Esquisabel
Journal:  Vaccine       Date:  2013-07-08       Impact factor: 3.641

Review 8.  Management of acute infectious diarrhea for children living in resource-limited settings.

Authors:  Miguel O'Ryan G; Liat Ashkenazi-Hoffnung; Miguel A O'Ryan-Soriano; Shai Ashkenazi
Journal:  Expert Rev Anti Infect Ther       Date:  2014-03-24       Impact factor: 5.091

Review 9.  Shigella vaccine development: prospective animal models and current status.

Authors:  Yeon-Jeong Kim; Sang-Gu Yeo; Jae-Hak Park; Hyun-Jeong Ko
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

10.  Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.

Authors:  Kirsi Tamminen; Suvi Lappalainen; Leena Huhti; Timo Vesikari; Vesna Blazevic
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

View more
  8 in total

Review 1.  What is the reservoir of emergent human norovirus strains?

Authors:  Stephanie M Karst; Ralph S Baric
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

2.  IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.

Authors:  Sanghita Sarkar; Michael S Piepenbrink; Madhubanti Basu; Juilee Thakar; Michael C Keefer; Ann J Hessell; Nancy L Haigwood; James J Kobie
Journal:  Vaccine       Date:  2019-03-27       Impact factor: 3.641

3.  Hydrological Regime and Water Shortage as Drivers of the Seasonal Incidence of Diarrheal Diseases in a Tropical Montane Environment.

Authors:  Laurie Boithias; Marc Choisy; Noy Souliyaseng; Marine Jourdren; Fabrice Quet; Yves Buisson; Chanthamousone Thammahacksa; Norbert Silvera; Keooudone Latsachack; Oloth Sengtaheuanghoung; Alain Pierret; Emma Rochelle-Newall; Sylvia Becerra; Olivier Ribolzi
Journal:  PLoS Negl Trop Dis       Date:  2016-12-09

Review 4.  Making sense of the cause of Crohn's - a new look at an old disease.

Authors:  Anthony W Segal
Journal:  F1000Res       Date:  2016-10-12

5.  Thiocarbamates from Moringa oleifera Seeds Bioactive against Virulent and Multidrug-Resistant Vibrio Species.

Authors:  Renata Albuquerque Costa; Oscarina Viana de Sousa; Ernesto Hofer; Jair Mafezoli; Francisco Geraldo Barbosa; Regine Helena Silva Dos Fernandes Vieira
Journal:  Biomed Res Int       Date:  2017-07-09       Impact factor: 3.411

Review 6.  Rotavirus Vaccines: a story of success with challenges ahead.

Authors:  Miguel O'Ryan
Journal:  F1000Res       Date:  2017-08-18

7.  Genomic characterization of the non-O1/non-O139 Vibrio cholerae strain that caused a gastroenteritis outbreak in Santiago, Chile, 2018.

Authors:  Mónica Arteaga; Juliana Velasco; Shelly Rodriguez; Maricel Vidal; Carolina Arellano; Francisco Silva; Leandro J Carreño; Roberto Vidal; David A Montero
Journal:  Microb Genom       Date:  2020-03

8.  Escherichia coli outer membrane protein F (OmpF): an immunogenic protein induces cross-reactive antibodies against Escherichia coli and Shigella.

Authors:  Xiao Wang; Da Teng; Qingfeng Guan; Ruoyu Mao; Ya Hao; Xiumin Wang; Junhu Yao; Jianhua Wang
Journal:  AMB Express       Date:  2017-07-19       Impact factor: 3.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.